Arbutus Biopharma Director Roger Sawhney Receives 78,800 Stock Options

This Form 4 filing reports that Roger Sawhney, a director of Arbutus Biopharma Corporation, received a grant of 78,800 stock options on June 8, 2026. The options have an exercise price of $4.24 per share, which reflects the closing price of the company's common shares on the Nasdaq Stock Market on the grant date. The options are fully vested and exercisable immediately upon grant and have an expiration date of June 8, 2036. The transaction represents an award of derivative securities (stock options) rather than direct common shares. As a director, Sawhney is required to report this transaction under Section 16 of the Securities Exchange Act of 1934. The filing was signed by Tuan Nguyen as attorney-in-fact for Roger Sawhney on June 10, 2026.